AstraZeneca and Ionis Pharmaceuticals have closed a previously announced commercialisation agreement to develop and market experimental therapy, eplontersen, previously called IONIS-TTR-LRX. The deal was announced earlier this month.
The move comes after the Drugs Controller General of India (DCGI) granted emergency use authorization (EUA) for the vaccine, dubbed ‘The World’s COVID-19 Vaccine’. Corbevax technology was engineered
Keytruda is Merck’s an anti-programmed death receptor-1 (PD-1) therapy that hinders the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It increases the ability of the body’s
The acquisition of 3DBT for the consideration amount is to be satisfied by the issuance to the sellers of a total of 33,900,003 consideration shares at 7.37 pence
A fully human biologic, Cosentyx is developed to directly target interleukin-17A (IL-17A), a cytokine. IL-17A is involved in the inflammation of plaque psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis
Trastuzumab is a monoclonal antibody intended to treat human epidermal growth factor receptor 2 positive (HER2-positive) breast and metastatic gastric cancers. The company aims to secure EMA approval
The agreement with the Government of the UK is subject to the local authorisation of the Covid-19 pill. Previously, the UK placed an order of 250,000 Paxlovid doses.
Molnupiravir is an orally administered form of a potent ribonucleoside analogue that blocks the SARS-CoV-2 replication. It is planned to be sold under the trademark Lagevrio in the
This brings the company’s total Series A funding raised to $107m. The financing was led by Third Rock Ventures and saw participation from Smilegate Investment, Schroders Capital, Alexandria
The long-acting injectable is indicated for use in adults and adolescents who are at risk of sexually acquiring HIV and test negative for HIV-1 before initiation. The regulatory
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.